A detailed history of Cooper Financial Group transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Cooper Financial Group holds 7,209 shares of GILD stock, worth $634,968. This represents 0.07% of its overall portfolio holdings.

Number of Shares
7,209
Previous 2,746 162.53%
Holding current value
$634,968
Previous $201,000 145.77%
% of portfolio
0.07%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 15, 2024

BUY
$63.15 - $72.88 $281,838 - $325,263
4,463 Added 162.53%
7,209 $494,000
Q1 2024

Apr 11, 2024

SELL
$71.58 - $87.29 $20,829 - $25,401
-291 Reduced 9.58%
2,746 $201,000
Q4 2023

Jan 16, 2024

BUY
$73.27 - $83.09 $222,520 - $252,344
3,037 New
3,037 $246,000
Q1 2023

May 10, 2023

BUY
$77.31 - $88.08 $41,979 - $47,827
543 Added 22.89%
2,915 $241,000
Q4 2022

Jan 13, 2023

BUY
$62.32 - $89.47 $147,823 - $212,222
2,372 New
2,372 $0
Q3 2020

Oct 09, 2020

SELL
$62.1 - $78.08 $284,666 - $357,918
-4,584 Closed
0 $0
Q2 2020

Jul 15, 2020

BUY
$72.34 - $84.0 $5,787 - $6,720
80 Added 1.78%
4,584 $353,000
Q1 2020

May 15, 2020

BUY
$62.63 - $80.22 $19,290 - $24,707
308 Added 7.34%
4,504 $337,000
Q4 2019

Jan 07, 2020

BUY
$61.62 - $67.78 $12,015 - $13,217
195 Added 4.87%
4,196 $273,000
Q3 2019

Oct 08, 2019

BUY
$62.51 - $69.0 $24,816 - $27,393
397 Added 11.02%
4,001 $254,000
Q2 2019

Jul 08, 2019

BUY
$61.87 - $69.38 $9,218 - $10,337
149 Added 4.31%
3,604 $243,000
Q1 2019

May 15, 2019

BUY
$62.53 - $70.05 $13,193 - $14,780
211 Added 6.5%
3,455 $225,000
Q4 2018

Jan 17, 2019

BUY
$60.54 - $79.0 $196,391 - $256,276
3,244 New
3,244 $203,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Cooper Financial Group Portfolio

Follow Cooper Financial Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cooper Financial Group, based on Form 13F filings with the SEC.

News

Stay updated on Cooper Financial Group with notifications on news.